Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine;Factores predisponentes al abandono del tratamiento preventivo en una serie de pacientes con migraña

Revista de Neurologia

Volumn 53, Issue 4, 2011, Pages 201-208

  Gracia Naya, Manuel ^a   Santos Lasaosa, Sonia ^b   Ríos Gómez, Consuelo ^c   Sánchez Valiente, Sara ^d   García Gomara, M José ^e   Latorre Jiménez, Ana M ^f   Artal Roy, Jorge ^a   Mauri Llerda, Osé A ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL DE BARBASTRO   (Spain)

^d HOSPITAL ROYO VILLANOVA   (Spain)

^e Hospital Comarcal de Calatayud   (Spain)

^f HOSPITAL SAN JORGE   (Spain)

Author keywords

Adherence to treatment; Dropping out of preventive treatment; Flunarizine; Migraine; Nadolol; Prophylaxis in migraine; Topiramate

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; FLUNARIZINE; NADOLOL; TOPIRAMATE;

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE PREDISPOSITION; DRUG ABUSE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; OUTCOME VARIABLE; PATIENT; PROSPECTIVE STUDY; SEIZURE;

EID: 80051867163     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5304.2011115     Document Type: Article

References (53)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-57.
2. Ferrari MD. Migraine. Lancet 1998; 35: 1043-51.
3. Gracia-Naya M, Latorre-Jiménez AM. Diferencias entre los pacientes con migraña enviados a una unidad de cefaleas o a una consulta general de neurología. Rev Neurol 2003; 37: 521-4.
4. Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin HR, Grotta JC. Headache in the Emergency Department. Headache 2001; 41: 537-41.
5. Láinez JM, Monzón MJ, and the Spanish Occupational Migraine Study Group. The socio-economic impact of migraine in Spain. In Olesen J, Steiner TJ, Lipton RB, eds. Reducing the burden of headache. Frontiers of Headache Research, vol. 11. Oxford: Oxford University Press; 2003. p. 255-9.
6. Fishman P, Black L. Indirect costs of migraine in a managed care population. Cephalalgia 1999; 19: 50-7.
7. Fernández-Concepción O, Canuet-Delis L. Discapacidad y calidad de vida en pacientes con migraña: factores determinantes. Rev Neurol 2003; 36: 1105-12.
8. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000; 57: 418-20.
9. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6: 429-40.
10. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62: 788-90.
11. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache 1987; 27: 102-6.
12. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004; 24: 1-160.
13. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al; Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6.
14. Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist 2006; 12: 204-13.
15. D'Amico D, Lanteri-Minet M. Migraine preventive therapy: selection of appropriate patients and general principles of management. Expert Rev Neurother 2006; 6: 1147-57.
16. Lipton, RB. Bigal, ME. Diamond, M. Freitag, F. Reed, ML. Stewart, WF. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9.
17. Rozen TD. Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective). Headache 2006; 46: 750-3.
18. Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, et al. Patients' preference for migraine preventive therapy. Headache 2007; 47: 540-5.
19. Kol CM, Dekker F, Neven AK, Assendelft WJ, Blom JW. Acceptance or rejection of prophylactic medicine in patients with migraine: a cross-sectional study. Br J Gen Pract 2008; 58: 98-101.
20. Pascual J. Migraña: tratamiento preventivo. In Mateos V,Pareja JA, Pascual J, eds. Tratado de cefaleas. Madrid: Luzán; 2009. p. 131-50.
21. Pascual-Gómez J. Papel de los neuromoduladores en el tratamiento preventivo de la migraña. Rev Neurol 2009; 49: 25-32.
22. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al; CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31: 542-59.
23. Gracia-Naya M, Latorre-Jiménez AM. Topiramato o flunaricina en el tratamiento preventivo de la migraña. Estudio comparativo de dos series de casos. Rev Neurol 2005; 41: 705-8.
24. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008; 118: 301-5.
25. Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología. Guía para el tratamiento de las cefaleas. Barcelona: Prous Science; 2006.
26. Evers S, Afra J, Frese A, Goasdsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-81.
27. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-4.
28. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, Arévalo MJ,et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-9.
29. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-50.
30. Gracia-Naya M, Alarcia-Alejos R, Modrego-Pardo PJ. Importancia de la migraña crónica en una consulta general de neurología. Rev Neurol 2008; 46: 577-81.
31. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia 2003; 23: 293-301.
32. Linde M, Jonsson P, Hedenrud T. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand 2008; 118: 367-72.
33. Evans RW, Linde M. Expert opinion: adherence to prophylactic migraine medication. Headache 2009; 49: 1054-8.
34. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C; GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to diseasemodifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 69-77.
35. Arroyo E, González M, Grau C, Arnal C, Bujanda M, De Castro P, et al. Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis. Neurologia 2010; 25: 544-51.
36. Rains JC, Lipchik GL, Penzien DB. Behavioral facilitation of medical treatment for headache -part I: review of headache treatment compliance. Headache 2006; 46: 1387-94.
37. Rains JC, Penzien DB, Lipchik GL. Behavioral facilitation of medical treatment for headache -part II: theoretical models and behavioral strategies for improving adherence. Headache 2006; 46: 1395-403.
38. D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 2008; 4: 1155-67.
39. Marinker M, Shaw J. Not to be taken as directed. BMJ 2003; 326: 348-9.
40. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43: 36-43.
41. Foley KA, Cady R, Martin V, Adelman J, Diamond M, Bell CF, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538-45.
42. Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007; 14: 900-6.
43. Gracia-Naya M, Sánchez-Valiente S, Latorre-Jiménez AM, Ríos-Gómez C, Santos-Lasaosa S, Mauri-Llerda JA, et al. Pacientes con cefalea y abuso de medicación. Indicadores de respuesta al tratamiento ambulatorio. Rev Neurol 2009; 49: 225-30.
44. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al; Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebocontrolled trial. Headache 2007; 47: 170-80.
45. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; Topmat-mig-201 (Top-chrome) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-23.
46. Gracia-Naya M, Latorre-Jiménez A, Ríos-Gómez C, Santos- Lasaosa S, Mauri JA, Sánchez-Valiente S, et al. Effectiveness of topiramate and flunarizine for chronic migraine: a comparative case-series study. Cephalalgia 2007; 27: 575-9.
47. Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009; 29: 1021-7.
48. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of botulinum toxin A and topiramate for the prophylactic treatment of chronic migraine. Headache 2011; 51: 21-32.
49. Saper JR, Lake AE 3rd. Borderline personality disorder and the chronic headache patient: review and management recommendations. Headache 2002; 42: 663-74.
50. Saper JR, Hamel RL, Lake AE. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 2005; 25: 545-6.
51. Sevillano-García MD, Manso-Calderón R, Cacabelos-Pérez P. Comorbilidad en la migraña: depresión, ansiedad, estrés e insomnio. Rev Neurol 2007; 45: 400-5.
52. Sala I, Roig C, Amador-Campos JA, García-Sánchez C, Rodríguez A, Díaz C, et al. Síntomas psicopatológicos en pacientes afectos de cefalea crónica con o sin fibromialgia. Rev Neurol 2009; 49: 281-7.
53. Mateos V, García-Moncó JC, Gómez-Beldarrain M, Armengol- Bertolín S, Larios C. Factores de personalidad, grado de discapacidad y abordaje terapéutico de los pacientes con migraña atendidos en primera consulta en neurología (estudio Psicomig). Rev Neurol 2011; 52: 131-8.